709 related articles for article (PubMed ID: 28529147)
41. A Randomized, Dose-Finding, Proof-of-Concept Study of Berberine Ursodeoxycholate in Patients With Primary Sclerosing Cholangitis.
Kowdley KV; Forman L; Eksteen B; Gunn N; Sundaram V; Landis C; Harrison SA; Levy C; Liberman A; Di Bisceglie AM; Hirschfield GM
Am J Gastroenterol; 2022 Nov; 117(11):1805-1815. PubMed ID: 36327436
[TBL] [Abstract][Full Text] [Related]
42. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D; Boudes PF; Swain MG; Bowlus CL; Galambos MR; Bacon BR; Doerffel Y; Gitlin N; Gordon SC; Odin JA; Sheridan D; Wörns MA; Clark V; Corless L; Hartmann H; Jonas ME; Kremer AE; Mells GF; Buggisch P; Freilich BL; Levy C; Vierling JM; Bernstein DE; Hartleb M; Janczewska E; Rochling F; Shah H; Shiffman ML; Smith JH; Choi YJ; Steinberg A; Varga M; Chera H; Martin R; McWherter CA; Hirschfield GM
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children.
Gilger MA; Gann ME; Opekun AR; Gleason WA
J Pediatr Gastroenterol Nutr; 2000 Aug; 31(2):136-41. PubMed ID: 10941964
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
47. Adjunct Fenofibrate Up-regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis.
Gallucci GM; Trottier J; Hemme C; Assis DN; Boyer JL; Barbier O; Ghonem NS
Hepatol Commun; 2021 Dec; 5(12):2035-2051. PubMed ID: 34558841
[TBL] [Abstract][Full Text] [Related]
48. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
49. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
[TBL] [Abstract][Full Text] [Related]
50. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
Smith T; Befeler AS
Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
[TBL] [Abstract][Full Text] [Related]
51. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study.
Olsson R; Boberg KM; de Muckadell OS; Lindgren S; Hultcrantz R; Folvik G; Bell H; Gangsøy-Kristiansen M; Matre J; Rydning A; Wikman O; Danielsson A; Sandberg-Gertzén H; Ung KA; Eriksson A; Lööf L; Prytz H; Marschall HU; Broomé U
Gastroenterology; 2005 Nov; 129(5):1464-72. PubMed ID: 16285948
[TBL] [Abstract][Full Text] [Related]
52. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
53. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
54. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
55. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study.
Eksteen B; Bowlus CL; Montano-Loza AJ; Lefebvre E; Fischer L; Vig P; Martins EB; Ahmad J; Yimam KK; Pockros PJ; Feld JJ; Minuk G; Levy C
Hepatol Commun; 2021 Mar; 5(3):478-490. PubMed ID: 33681680
[TBL] [Abstract][Full Text] [Related]
57. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
58. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.
Fickert P; Pollheimer MJ; Silbert D; Moustafa T; Halilbasic E; Krones E; Durchschein F; Thüringer A; Zollner G; Denk H; Trauner M
J Hepatol; 2013 Jun; 58(6):1201-8. PubMed ID: 23369794
[TBL] [Abstract][Full Text] [Related]
59. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.
Stiehl A
Scand J Gastroenterol Suppl; 1994; 204():59-61. PubMed ID: 7824879
[TBL] [Abstract][Full Text] [Related]
60. The management of primary sclerosing cholangitis.
Mitchell SA; Chapman RW
Clin Liver Dis; 1998 May; 2(2):353-72, x. PubMed ID: 15560037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
